Skip Navigation


European Heart Journal Advance Access originally published online on August 16, 2005
European Heart Journal 2005 26(22):2387-2395; doi:10.1093/eurheartj/ehi436
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/22/2387    most recent
ehi436v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Susen, S.
Right arrow Articles by Van Belle, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Susen, S.
Right arrow Articles by Van Belle, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization

Sophie Susen2,4,{dagger}, Karine Sautière1,4,{dagger}, Frédéric Mouquet1,4, François Cuilleret1, Akram Chmaït1, Eugène P. McFadden1, Bernadette Hennache3, Florence Richard5, Pascal de Groote1, Jean-Marc Lablanche1, Jean Dallongeville5, Christophe Bauters1,5, Brigitte Jude2,4 and Eric Van Belle1,4,*

1Department of Cardiology, University Hospital, Lille, France
2Department of Hematology, University Hospital, Lille, France
3Department of Biochemistry, University Hospital, Lille, France
4INSERM-ESPRI 2004–EA 2693, Lille II University, Lille, France
5INSERM-U508, Institut Pasteur, Lille, France

Received 9 May 2005; revised 18 June 2005; accepted 7 July 2005; online publish-ahead-of-print 16 August 2005.

* Corresponding author: Service de Cardiologie B et Hémodynamique, Hôpital Cardiologique, Centre Hospitalier Régional, 59037 Lille Cedex, France. Tel: +33 3 20 44 50 08; fax: +33 3 20 44 51 30. E-mail address: ericvanbelle{at}aol.com

Aims To evaluate, in patients referred for elective percutaneous coronary revascularization (PCR) without heparin pre-treatment, the relationship between baseline serum levels of the angiogenic growth factors, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), and clinical outcome.

Methods and results In 488 consecutive patients undergoing elective coronary angioplasty, hsC-reactive protein, HGF, and VEGF levels were measured before heparin administration. The primary endpoint, a composite of death and myocardial infarction, occurred in 44 patients at a median follow-up of 14.9 months. At baseline, VEGF levels were related to C-reactive protein levels and inversely related to age; HGF levels were related to C-reactive protein levels, diabetes, and recent clinical instability. In the univariate analysis, HGF had a significant positive relationship (P=0.003) with the primary endpoint. A similar trend was observed for VEGF (P=0.11). The only three variables significantly associated with the primary endpoint in the multivariable Cox model were HGF (P=0.004), C-reactive protein (P=0.007), and diabetes (P=0.04).

Conclusion Our results demonstrate that in patients, without heparin pre-treatment, referred for PCR, a high serum level of HGF is an independent predictor of clinical events during follow-up and is correlated with other surrogate measures of the activity of atherosclerosis.

Key Words: Angioplasty • Growth factors • Diabetes mellitus • C-reactive protein • Clinical outcome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
L. N. Bell, J. L. Ward, M. Degawa-Yamauchi, J. E. Bovenkerk, R. Jones, B. M. Cacucci, C. E. Gupta, C. Sheridan, K. Sheridan, S. S. Shankar, et al.
Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity
Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E843 - E848.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.